Quantitative assessment of treatment effect in tumor
MPM, NSCLC, tumor, Tumor, TNBC
NON-SMALL CELL LUNG CANCER, TUMOR, INFILTRATION, TUMOR, TRIPLE NEGATIVE BREAST CANCER, ADENOCARCINOMA, NSCLC, MALIGNANT PLEURAL MESOTHELIOMA, SQUAMOUS CELL CARCINOMA
Resected samples from 16 patients were stained with hematoxylin and eosin and independently scored semi-quantitatively for tumor-cell density and immune-cell density by two pathologists (Tumor and immune cell scoring of tumor specimens stained with hematoxylin and eosin.– Insufficient sampleADC, adenocarcinoma; MPM, malignant pleural mesothelioma; NSCLC, non-small cell lung cancer; PFU, plaque-forming units; SCC, squamous cell carcinoma; TNBC, triple negative breast cancer.Tumor cell and immune cell density scoring before and after Olvi-vec therapy. When matched tumor specimens were stained using multiplex immunofluorescence and then compared (n=4), mean CD8+ cells per mmImmune cell infiltration in matched MPM tumor specimens before and after Olvi-vec therapy. Immune cell infiltration ratios in all MPM tumor specimens before and after Olvi-vec therapy. Gene expression analysis of pre- and post-treatment tumor specimens (n=16), using nCounter immune cell type scoring module, revealed increased scores (i.e., change in score by 1 unit, indicating twice the abundance of that cell type) for CD45+, Th1+, Tregs, CD8+, exhausted CD8+, NK+, cytotoxic cells, dendritic cells, macrophage, and neutrophil immune cell populations in post-treatment tumor specimens compared to pre-treatment specimens (Immune cell scores based on mRNA transcript abundance before and after Olvi-vec therapy. mRNA transcript expression of immune-modulatory proteins before and after Olvi-vec therapy. 